Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1, Nimotuzumab, and Capecitabine in Platinum-Resistant NPC
NCT06259721Phase 2Recruiting
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab and capecitabine in nasopharyngeal carcinoma (NPC). Primary endpoint: Objective Response Rate at 6 months. Started Feb 2024; status: recruiting.
02
Drugs
nimotuzumabcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06259721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259721.